Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Ralvic Chrono** is a Unipharma prolonged-release oral tablet formulation containing sodium valproate and valproic acid, supplied in strengths equivalent to 300 mg or 500 mg sodium valproate. It is an anticonvulsant valproate formulation marketed for epilepsy, including generalized and focal seizure disorders, and also for mania when other therapies are inadequate or inappropriate; the product information also provides dosing for migraine prevention. Valproate is thought to enhance inhibitory gamma-aminobutyric acid neurotransmission in the central nervous system. ([unipharma-sy.com](https://www.unipharma-sy.com/Product/526))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Ralvic Chrono.